Comparison Of The Effects Of Bevacizumab (Bv) In Combination With Chemotherapy (Ct) And Ct Alone On The Incidence Of Brain Metastases (Bm) In Non-Small Cell Lung Cancer (Nsclc): A Retrospective Clinical Analysis

e19044 Background: The incidence of BM of advanced NSCLC is 20-40%, and thereu0027s a lack of effective treatment. This study aims to investigate the value of the angiogenesis marker VEGF in predicting the risk of BM in patients (pts) with NSCLC receiving CT+BV or CT alone and to explore the cumulative risk of BM of NSCLC with high VEGF expression that treated with BV. Methods: Pts with stage IIIB/IV NSCLC underwent CT and/or targeted therapy from 2008-1 to 2010-12 were included. Semi-quantitative detection of VEGF expression was carried out using conventional immunohistochemical staining of lung tissue specimens. Pts experienced BM prior to treatment were excluded. Pts underwent gemcitabine/carboplatin (GC) + BV treatment were included in observation group; pts underwent GC were included in control group. The cumulative risk of BM was calculated using death as a competing risk. Results: 177 pts were included (118 in BV+CT group; 59 in CT group). The median follow-up duration was 18.7 months. Up to 2012-12-31...